<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357861</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.290</org_study_id>
    <nct_id>NCT03357861</nct_id>
  </id_info>
  <brief_title>Cancer Patients Treated With Immunotherapy in Intensive Care Unit</brief_title>
  <acronym>IMMUNO-REA</acronym>
  <official_title>Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This work aims to describe the characteristics and methods of management of patients&#xD;
      suffering from a solid tumor treated with immunotherapy admitted to intensive care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The place of checkpoint inhibitors (anti-PD-1 and PD-L-1) is currently validated in the&#xD;
      management of melanoma and metastatic non-small cell lung cancer. The toxicity profile is&#xD;
      specific with adverse effects related to immunity. Some side effects (myocarditis, colitis,&#xD;
      interstitial lung disease, etc.) can be severe and patient could be hospitalized in intensive&#xD;
      care unit.&#xD;
&#xD;
      The question of immunotherapy's imputability in the acute disease is becoming more frequent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">August 23, 2021</completion_date>
  <primary_completion_date type="Actual">August 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the imputability of immunotherapy in the ICU admission reason for lung cancer patients treated by immunotherapy.</measure>
    <time_frame>At ICU discharge (maximum 30 days)</time_frame>
    <description>Description of ICU admission reason (immunotherapy toxicity versus other) for lung cancer patients treated by immunotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the immunosuppressive treatments prescribed during the stay in intensive care for the patient's care.</measure>
    <time_frame>At ICU discharge (maximum 30 days)</time_frame>
    <description>immunosuppressive treatments in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of ICU survival</measure>
    <time_frame>At ICU discharge (maximum 60 days)</time_frame>
    <description>ICU survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of hospital survival</measure>
    <time_frame>At hospital discharge (maximum 60 days)</time_frame>
    <description>Hospital survival</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Cancer</condition>
  <condition>Critical Illness</condition>
  <condition>Immunotherapy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients treated with anti-CTLA4 and/or anti-PD-1 / anti-PD-L1 or up to 6 months&#xD;
        after stopping admitted in ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; or = 18 years old;&#xD;
&#xD;
          -  with a solid tumor;&#xD;
&#xD;
          -  Treatment with anti-CTLA4 and / or anti-PD-1 / PDL-1 still in progress or up to 6&#xD;
             months after stopping;&#xD;
&#xD;
          -  Admitted to resuscitation or continuous care in an unprogrammed way, whatever the&#xD;
             reason.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minors;&#xD;
&#xD;
          -  Pregnant or lactating woman;&#xD;
&#xD;
          -  Admission after surgery of a scheduled surgery or for the security of procedure;&#xD;
&#xD;
          -  Anti-CTLA4 and / or anti-PD-1 / PDL-1 treatment stopped for more than 6 months;&#xD;
&#xD;
          -  Subject under guardianship or deprivation of liberty;&#xD;
&#xD;
          -  Refusal of consent;&#xD;
&#xD;
          -  No affiliation to a health insurance scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Claire TOFFART, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversityHospital Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversityHospitalGrenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>checkpoint inhibitors</keyword>
  <keyword>adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

